Curcumin, a potential therapeutic candidate for retinal diseases

Molecular Nutrition and Food Research

Volumn 57, Issue 9, 2013, Pages 1557-1568

  Wang, Lei Lei ^a   Sun, Yue ^a   Huang, Kun ^b,c   Zheng, Ling ^a  

^a WUHAN UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c Wuhan Institute of Biotechnology   (China)

Author keywords

Anti inflammation; Antioxidative; Curcumin; Epigenetics; Retinal diseases

Indexed keywords

CURCUMA LONGA;

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CURCUMIN;

ANIMAL; ANTI-INFLAMMATION; CHEMISTRY; CLINICAL TRIAL (TOPIC); CURCUMA; DIABETIC RETINOPATHY; DISEASE MODEL; EPIGENETICS; GLAUCOMA; HUMAN; INFLAMMATION; RETINA DISEASE; RETINA MACULA DEGENERATION; RETINITIS PIGMENTOSA; RETINOBLASTOMA; REVIEW; VITREORETINOPATHY;

ANTI-INFLAMMATION; ANTIOXIDATIVE; CURCUMIN; EPIGENETICS; RETINAL DISEASES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; CURCUMA; CURCUMIN; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; GLAUCOMA; HUMANS; INFLAMMATION; MACULAR DEGENERATION; RETINAL DISEASES; RETINITIS PIGMENTOSA; RETINOBLASTOMA; VITREORETINOPATHY, PROLIFERATIVE;

EID: 84883458546     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201200718     Document Type: Review

References (118)

1. Govindarajan, V. S., Turmeric-chemistry, technology, and quality. Crit. Rev. Food Sci. Nutr. 1980, 12, 199-301.
2. Ammon, H. P., Wahl, M. A., Pharmacology of Curcuma longa. Planta. Medica. 1991, 57, 1-7.
3. Krishnaswamy, K., Traditional Indian spices and their health significance. Asia Pac. J. Clin. Nutr. 2008, 17(Suppl 1), 265-268.
4. Miriyala, S., Panchatcharam, M., Rengarajulu, P., Cardioprotective effects of curcumin. Adv. Exp. Med. Biol. 2007, 595, 359-377.
5. Wongcharoen, W., Phrommintikul, A., The protective role of curcumin in cardiovascular diseases. Int. J. Cardiol. 2009, 133, 145-151.
6. Cole, G. M., Teter, B., Frautschy, S. A., Neuroprotective effects of curcumin. Adv. Exp. Med. Biol. 2007, 595, 197-212.
7. Feldheim, D. A., O'Leary, D. D., Visual map development: bidirectional signaling, bifunctional guidance molecules, and competition. Cold Spring Harb. Perspect. Biol. 2010, 2, a001768.
8. Reese, B. E., Development of the retina and optic pathway. Vis. Res. 2011, 51, 613-632.
9. Fruttiger, M., Development of the retinal vasculature. Angiogenesis 2007, 10, 77-88.
10. Zhou, H., Beevers, C. S., Huang, S., The targets of curcumin. Curr. Drug Targets 2011, 12, 332-347.
11. Ahsan, H., Parveen, N., Khan, N. U., Hadi, S. M., Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin. Chem. Biol. Interact. 1999, 121, 161-175.
12. Osawa, T., Sugiyama, Y., Inayoshi, M., Kawakishi, S., Antioxidative activity of tetrahydrocurcuminoids. Biosci. Biotechnol. Biochem. 1995, 59, 1609-1612.
13. Calabrese, V., Bates, T. E., Mancuso, C., Cornelius, C. et al., Curcumin and the cellular stress response in free radical-related diseases. Mol. Nutr. Food Res. 2008, 52, 1062-1073.
14. Sugiyama, Y., Kawakishi, S., Osawa, T., Involvement of the beta-diketone moiety in the antioxidative mechanism of tetrahydrocurcumin. Biochem. Pharmacol. 1996, 52, 519-525.
15. Priyadarsini, K. I., Maity, D. K., Naik, G. H., Kumar, M. S. et al., Role of phenolic O-H and methylene hydrogen on the free radical reactions and antioxidant activity of curcumin. Free Radic. Biol. Med. 2003, 35, 475-484.
16. Zinov'eva, V. N., Ostrovskii, O. V., Free radical oxidation of DNA and its biomarker oxidized guanosine(8-oxodG). Voprosy meditsinskoi khimii 2002, 48, 419-431.
17. Pinlaor, S., Yongvanit, P., Prakobwong, S., Kaewsamut, B. et al., Curcumin reduces oxidative and nitrative DNA damage through balancing of oxidant-antioxidant status in hamsters infected with Opisthorchis viverrini. Mol. Nutr. Food Res. 2009, 53, 1316-1328.
18. Molina-Jijon, E., Tapia, E., Zazueta, C., El Hafidi, M. et al., Curcumin prevents Cr(VI)-induced renal oxidant damage by a mitochondrial pathway. Free Radic. Biol. Med. 2011, 51, 1543-1557.
19. Gonzalez-Salazar, A., Molina-Jijon, E., Correa, F., Zarco-Marquez, G. et al., Curcumin protects from cardiac reperfusion damage by attenuation of oxidant stress and mitochondrial dysfunction. Cardiovasc Toxicol. 2011, 11, 357-364.
20. Hybertson, B. M., Gao, B., Bose, S. K., McCord, J. M., Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol. Aspects Med. 2011, 32, 234-246.
21. Balogun, E., Hoque, M., Gong, P., Killeen, E. et al., Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem. J. 2003, 371, 887-895.
22. Kim, Y. M., Pae, H. O., Park, J. E., Lee, Y. C. et al., Heme oxygenase in the regulation of vascular biology: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 2011, 14, 137-167.
23. Balasubramanyam, K., Varier, R. A., Altaf, M., Swaminathan, V. et al., Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 2004, 279, 51163-51171.
24. Marcu, M. G., Jung, Y. J., Lee, S., Chung, E. J. et al., Curcumin is an inhibitor of p300 histone acetylatransferase. Med. Chem. 2006, 2, 169-174.
25. Khan, O., La Thangue, N. B., HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol. 2012, 90, 85-94.
26. Iyer, A., Fairlie, D. P., Brown, L., Lysine acetylation in obesity, diabetes and metabolic disease. Immunol. Cell Biol. 2012, 90, 39-46.
27. Wang, J., Wu, Z., Li, D., Li, N. et al., Nutrition, epigenetics, and metabolic syndrome. Antioxid. Redox Signal. 2012, 17, 282-301.
28. Kalkhoven, E., CBP and p300: HATs for different occasions. Biochem. Pharmacol. 2004, 68, 1145-1155.
29. Morimoto, T., Sunagawa, Y., Kawamura, T., Takaya, T. et al., The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J. Clin. Invest. 2008, 118, 868-878.
30. Balasubramanian, V., Sterling, P., Receptive fields and functional architecture in the retina. J. Physiol. 2009, 587, 2753-2767.
31. Cheung, N., Mitchell, P., Wong, T. Y., Diabetic retinopathy. Lancet 2010, 376, 124-136.
32. Baltmr, A., Duggan, J., Nizari, S., Salt, T. E. et al., Neuroprotection in glaucoma-is there a future role? Exp. Eye Res. 2010, 91, 554-566.
33. Beatty, S., Koh, H., Phil, M., Henson, D. et al., The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. 2000, 45, 115-134.
34. Zhang, X., Saaddine, J. B., Chou, C. F., Cotch, M. F. et al., Prevalence of diabetic retinopathy in the United States, 2005-2008.J. Am. Med. Assoc. 2010, 304, 649-656.
35. Frank, R. N., Diabetic retinopathy. N. Engl. J. Med. 2004, 350, 48-58.
36. Arden, G. B., Sivaprasad, S., The pathogenesis of early retinal changes of diabetic retinopathy. Doc. Ophthalmol. 2012, 124, 15-26.
37. Whitmire, W., Al-Gayyar, M. M., Abdelsaid, M., Yousufzai, B. K. et al., Alteration of growth factors and neuronal death in diabetic retinopathy: what we have learned so far. Mol. Vis. 2011, 17, 300-308.
38. Ozawa, Y., Kurihara, T., Sasaki, M., Ban, N. et al., Neural degeneration in the retina of the streptozotocin-induced type 1 diabetes model. Exp. Diabetes Res. 2011, 2011, 1-7.
39. Rema, M., Pradeepa, R., Diabetic retinopathy: an Indian perspective. Indian J. Med. Res. 2007, 125, 297-310.
40. Kowluru, R. A., Kanwar, M., Effects of curcumin on retinal oxidative stress and inflammation in diabetes. Nutr. Metab. 2007, DOI:10.1186/1743-7075-4-8.
41. Mrudula, T., Suryanarayana, P., Srinivas, P. N., Reddy, G. B., Effect of curcumin on hyperglycemia-induced vascular endothelial growth factor expression in streptozotocin-induced diabetic rat retina. Biochem. Biophys. Res. Commun. 2007, 361, 528-532.
42. Gupta, S. K., Kumar, B., Nag, T. C., Agrawal, S. S. et al., Curcumin prevents experimental diabetic retinopathy in rats through its hypoglycemic, antioxidant, and anti-inflammatory mechanisms. J. Ocul. Pharmacol. Ther. 2011, 27, 123-130.
43. Kowluru, R. A., Chan, P. S., Oxidative stress and diabetic retinopathy. Exp. Diabetes Res. 2007, 2007, 1-12.
44. Arden, G. B., Sivaprasad, S., Hypoxia and oxidative stress in the causation of diabetic retinopathy. Curr. Diabetes Rev. 2011, 7, 291-304.
45. Lu, S. C., Glutathione synthesis. Biochim. Biophys. Acta 2012, DOI: 10.1016/j.bbagen.2012.09.008.
46. Kern, T. S., Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp. Diabetes Res. 2007, 2007, 1-14.
47. Zheng, L., Szabo, C., Kern, T. S., Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 2004, 53, 2960-2967.
48. Zheng, L., Howell, S. J., Hatala, D. A., Huang, K. et al., Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes 2007, 56, 337-345.
49. Zheng, L., Du, Y., Miller, C., Gubitosi-Klug, R. A. et al., Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia 2007, 50, 1987-1996.
50. Zhong, Q., Kowluru, R. A., Role of histone acetylation in the development of diabetic retinopathy and the metabolic memory phenomenon. J. Cell. Biochem. 2010, 110, 1306-1313.
51. Perrone, L., Devi, T. S., Hosoya, K., Terasaki, T. et al., Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J. Cell. Physiol. 2009, 221, 262-272.
52. Kadiyala, C. S., Zheng, L., Du, Y., Yohannes, E. et al., Acetylation of retinal histones in diabetes increases inflammatory proteins: acetylation of retinal histones in diabetes increases inflammatory proteins effects of minocycline and manipulation of histone acetyl transferase (HAT) and histone deacetylase (HDAC). J. Biol. Chem. 2012, 287, 25869-25880.
53. Wang, L. L., Chen, H., Huang, K., Zheng, L., Elevated histone acetylations in Muller cell contribute to inflammation: a novel inhibitory effect of minocycline. Glia 2012, 60, 1896-1905.
54. Kaur, H., Chen, S., Xin, X., Chiu, J. et al., Diabetes-induced extracellular matrix protein expression is mediated by transcription coactivator p300. Diabetes 2006, 55, 3104-3111.
55. Wang, C., George, B., Chen, S., Feng, B. et al., Genotoxic stress and activation of novel DNA repair enzymes in human endothelial cells and in the retinas and kidneys of streptozotocin diabetic rats. Diabetes Metab. Res. Rev. 2012, 28, 329-337.
56. Robinson, C. J., Stringer, S. E., The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sc. 2001, 114, 853-865.
57. Thurston, G., Complementary actions of VEGF and angiopoietin-1 on blood vessel growth and leakage. J. Anat. 2002, 200, 575-580.
58. Jeganathan, V. S., Anti-angiogenesis drugs in diabetic retinopathy. Curr. Pharm. Biotechnol. 2011, 12, 369-372.
59. Willard, A. L., Herman, I. M., Vascular complications and diabetes: current therapies and future challenges. J. Ophthalmol. 2012, 2012, 1-14.
60. Salvucci, O., Basik, M., Yao, L., Bianchi, R. et al., Evidence for the involvement of SDF-1 and CXCR4 in the disruption of endothelial cell-branching morphogenesis and angiogenesis by TNF-alpha and IFN-gamma. J. Leukoc. Biol. 2004, 76, 217-226.
61. Sameermahmood, Z., Balasubramanyam, M., Saravanan, T., Rema, M., Curcumin modulates SDF-1alpha/CXCR4-induced migration of human retinal endothelial cells (HRECs). Invest. Ophthalmol. Vis. Sci. 2008, 49, 3305-3311.
62. Premanand, C., Rema, M., Sameer, M. Z., Sujatha, M. et al., Effect of curcumin on proliferation of human retinal endothelial cells under in vitro conditions. Invest. Ophthalmol. Vis. Sci. 2006, 47, 2179-2184.
63. Ehring, G. R., Szabo, I. L., Jones, M. K., Sarfeh, I. J. et al., ATP-induced CA2+-signaling enhances rat gastric microvascular endothelial cell migration. J. Physiol. Pharmacol. 2000, 51, 799-811.
64. Elner, V. M., Scales, W., Elner, S. G., Danforth, J. et al., Interleukin-6 (IL-6) gene expression and secretion by cytokine-stimulated human retinal pigment epithelial cells. Exp. Eye Res. 1992, 54, 361-368.
65. Campochiaro, P. A., Cytokine production by retinal pigmented epithelial cells. Int. Rev. Cytol. 1993, 146, 75-82.
66. Bian, Z. M., Elner, V. M., Yoshida, A., Kunkel, S. L. et al., Signaling pathways for glycated human serum albumin-induced IL-8 and MCP-1 secretion in human RPE cells. Invest. Ophthalmol. Vis. Sci. 2001, 42, 1660-1668.
67. Leiderman, Y. I., Miller, J. W., Proliferative vitreoretinopathy: pathobiology and therapeutic targets. Semin. Ophthalmol. 2009, 24, 62-69.
68. Hiscott, P., Sheridan, C., Magee, R. M., Grierson, I., Matrix and the retinal pigment epithelium in proliferative retinal disease. Prog. Retin. Eye Res. 1999, 18, 167-190.
69. Gong, L., Jiang, D., Zhu, X., Guo, L., Curcumin inhibits the proliferation of cultured human fetal retinal pigment epithelium cells. Yan Ke Xue Bao 2004, 20, 246-248, 258.
70. An, J. B., Ma, J. X., Liu, D. Y., Gao, Y. J. et al., The effect of curcumin on DNA content, mitochondrial transmembrane potential and calcium of rabbit cultured retinal pigment epithelial cells. Zhonghua Yan Ke Za Zhi 2009, 45, 210-215.
71. Alex, A. F., Spitznas, M., Tittel, A. P., Kurts, C. et al., Inhibitory effect of epigallocatechin gallate (EGCG), resveratrol, and curcumin on proliferation of human retinal pigment epithelial cells in vitro. Curr. Eye Res. 2010, 35, 1021-1033.
72. Levin, L. A., Retinal ganglion cells and neuroprotection for glaucoma. Surv. Ophthalmol. 2003, 48(Suppl 1), S21-24.
73. Almasieh, M., Wilson, A. M., Morquette, B., Cueva Vargas, J. L. et al., The molecular basis of retinal ganglion cell death in glaucoma. Prog. Retin Eye Res. 2012, 31, 152-181.
74. Teus, M. A., Castejon, M. A., Calvo, M. A., Perez-Salaices, P. et al., Intraocular pressure as a risk factor for visual field loss in pseudoexfoliative and in primary open-angle glaucoma. Ophthalmology 1998, 105, 2225-2229; discussion 2229-2230.
75. Osborne, N. N., Casson, R. J., Wood, J. P., Chidlow, G. et al., Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog. Retin. Eye Res. 2004, 23, 91-147.
76. Wang, L., Li, C., Guo, H., Kern, T. S. et al., Curcumin inhibits neuronal and vascular degeneration in retina after ischemia and reperfusion injury. PLoS One 2011, 6, e23194.
77. Westermann, B., Mitochondrial fusion and fission in cell life and death. Nat. Rev. Mol. Cell Biol. 2010, 11, 872-884.
78. Zuchner, S., Mersiyanova, I. V., Muglia, M., Bissar-Tadmouri, N. et al., Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat. Genet. 2004, 36, 449-451.
79. Misko, A. L., Sasaki, Y., Tuck, E., Milbrandt, J. et al., Mitofusin2 mutations disrupt axonal mitochondrial positioning and promote axon degeneration. J. Neurosci. 2012, 32, 4145-4155.
80. Wax, M. B., Tezel, G., Neurobiology of glaucomatous optic neuropathy: diverse cellular events in neurodegeneration and neuroprotection. Mol. Neurobiol. 2002, 26, 45-55.
81. Matteucci, A., Frank, C., Domenici, M. R., Balduzzi, M. et al., Curcumin treatment protects rat retinal neurons against excitotoxicity: effect on N-methyl-D: -aspartate-induced intracellular Ca(2+) increase. Exp. Brain Res. 2005, 167, 641-648.
82. Matteucci, A., Cammarota, R., Paradisi, S., Varano, M. et al., Curcumin protects against NMDA-induced toxicity: a possible role for NR2A subunit. Invest. Ophthalmol. Vis. Sci. 2010, 52, 1070-1077.
83. Krishnamoorthy, R. R., Agarwal, P., Prasanna, G., Vopat, K. et al., Characterization of a transformed rat retinal ganglion cell line. Brain Res. Mol. Brain Res. 2001, 86, 1-12.
84. Burugula, B., Ganesh, B. S., Chintala, S. K., Curcumin attenuates staurosporine-mediated death of retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 2011, 52, 4263-4273.
85. Lim, L. S., Mitchell, P., Seddon, J. M., Holz, F. G. et al., Age-related macular degeneration. Lancet 2012, 379, 1728-1738.
86. Bird, A. C., Bressler, N. M., Bressler, S. B., Chisholm, I. H. et al., An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv. Ophthalmol. 1995, 39, 367-374.
87. Ding, X., Patel, M., Chan, C. C., Molecular pathology of age-related macular degeneration. Prog. Retin. Eye Res. 2009, 28, 1-18.
88. Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Jr., Feinsod, M. et al., Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 2004, 351, 2805-2816.
89. Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G. et al., Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355, 1432-1444.
90. Dixon, J. A., Oliver, S. C., Olson, J. L., Mandava, N., VEGF trap-eye for the treatment of neovascular age-related macular degeneration. Expert Opin. Investig. Drugs 2009, 18, 1573-1580.
91. Demontis, G. C., Longoni, B., Marchiafava, P. L., Molecular steps involved in light-induced oxidative damage to retinal rods. Invest. Ophthalmol. Vis. Sci. 2002, 43, 2421-2427.
92. Donoso, L. A., Kim, D., Frost, A., Callahan, A. et al., The role of inflammation in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. 2006, 51, 137-152.
93. Marc, R. E., Jones, B. W., Watt, C. B., Vazquez-Chona, F. et al., Extreme retinal remodeling triggered by light damage: implications for age related macular degeneration. Mol. Vis. 2008, 14, 782-806.
94. Mandal, M. N., Patlolla, J. M., Zheng, L., Agbaga, M. P. et al., Curcumin protects retinal cells from light-and oxidant stress-induced cell death. Free Radic. Biol. Med. 2009, 46, 672-679.
95. Woo, J. M., Shin, D. Y., Lee, S. J., Joe, Y. et al., Curcumin protects retinal pigment epithelial cells against oxidative stress via induction of heme oxygenase-1 expression and reduction of reactive oxygen. Mol. Vis. 2012, 18, 901-908.
96. Rivolta, C., Sharon, D., DeAngelis, M. M., Dryja, T. P., Retinitis pigmentosa and allied diseases: numerous diseases, genes, and inheritance patterns. Hum. Mol. Genet. 2002, 11, 1219-1227.
97. Dryja, T. P., McGee, T. L., Reichel, E., Hahn, L. B. et al., A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature 1990, 343, 364-366.
98. Saliba, R. S., Munro, P. M., Luthert, P. J., Cheetham, M. E., The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation. J. Cell Sci. 2002, 115, 2907-2918.
99. Illing, M. E., Rajan, R. S., Bence, N. F., Kopito, R. R., A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. J. Biol. Chem. 2002, 277, 34150-34160.
100. Khajavi, M., Inoue, K., Wiszniewski, W., Ohyama, T. et al., Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants. Am. J. Hum. Genet. 2005, 77, 841-850.
101. Vasireddy, V., Chavali, V. R., Joseph, V. T., Kadam, R. et al., Rescue of photoreceptor degeneration by curcumin in transgenic rats with P23H rhodopsin mutation. PLoS One 2011, 6, e21193.
102. Dimaras, H., Kimani, K., Dimba, E. A., Gronsdahl, P. et al., Retinoblastoma. Lancet 2012, 379, 1436-1446.
103. Burkhart, D. L., Sage, J., Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat. Rev. Cancer 2008, 8, 671-682.
104. Weinberg, R. A., The retinoblastoma protein and cell cycle control. Cell 1995, 81, 323-330.
105. Henry, D. O., Moskalenko, S. A., Kaur, K. J., Fu, M. et al., Ral GTPases contribute to regulation of cyclin D1 through activation of NF-kappaB. Mol. Cell. Biol. 2000, 20, 8084-8092.
106. Mukhopadhyay, A., Banerjee, S., Stafford, L. J., Xia, C. et al., Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 2002, 21, 8852-8861.
107. Srivastava, R. K., Chen, Q., Siddiqui, I., Sarva, K. et al., Linkage of curcumin-induced cell cycle arrest and apoptosis by cyclin-dependent kinase inhibitor p21(/WAF1/CIP1). Cell Cycle 2007, 6, 2953-2961.
108. Sreenivasan, S., Thirumalai, K., Danda, R., Krishnakumar, S., Effect of curcumin on miRNA expression in human Y79 retinoblastoma cells. Curr. Eye Res. 2012, 37, 421-428.
109. Seme, M. T., Summerfelt, P., Neitz, J., Eells, J. T. et al., Differential recovery of retinal function after mitochondrial inhibition by methanol intoxication. Invest. Ophthalmol. Vis. Sci. 2001, 42, 834-841.
110. Seme, M. T., Summerfelt, P., Henry, M. M., Neitz, J. et al., Formate-induced inhibition of photoreceptor function in methanol intoxication. J. Pharmacol. Exp. Ther. 1999, 289, 361-370.
111. Chirapapaisan, N., Uiprasertkul, M., Chuncharunee, A., The effect of coenzyme Q10 and curcumin on chronic methanol intoxication induced retinopathy in rats. J. Med. Assoc. Thai. 2012, 95(Suppl 4), S76-81.
112. Lal, B., Kapoor, A. K., Asthana, O. P., Agrawal, P. K. et al., Efficacy of curcumin in the management of chronic anterior uveitis. Phytother. Res. 1999, 13, 318-322.
113. Allegri, P., Mastromarino, A., Neri, P., Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment. Long-term follow-up. Clin. Ophthalmol. 2010, 4, 1201-1206.
114. Mazzolani, F., Pilot study of oral administration of a curcumin-phospholipid formulation for treatment of central serous chorioretinopathy. Clin. Ophthalmol. 2012, 6, 801-806.
115. Moorthy, R. S., Mermoud, A., Baerveldt, G., Minckler, D. S. et al., Glaucoma associated with uveitis. Surv. Ophthalmol. 1997, 41, 361-394.
116. Lao, C. D., Ruffin, M. T. T., Normolle, D., Heath, D. D. et al., Dose escalation of a curcuminoid formulation. BMC Complementary Altern. Med. 2006, 6, 10, doi:10.1186/1472-6882-6-10.
117. Anand, P., Kunnumakkara, A. B., Newman, R. A., Aggarwal, B. B., Bioavailability of curcumin: problems and promises. Mol. Pharm. 2007, 4, 807-818.
118. Marczylo, T. H., Verschoyle, R. D., Cooke, D. N., Morazzoni, P. et al., Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother. Pharmacol. 2007, 60, 171-177.